lineage conversion of one somatic cell type to another is an attractive approach for generating specific human cell types. lineage conversion can be direct, in the absence of proliferation and multipotent progenitor generation, or indirect, by the generation of expandable multipotent progenitor states. We report the development of a reprogramming methodology in which cells transition through a plastic intermediate state, induced by brief exposure to reprogramming factors, followed by differentiation. We use this approach to convert human fibroblasts to mesodermal progenitor cells, including by non-integrative approaches. these progenitor cells demonstrated bipotent differentiation potential and could generate endothelial and smooth muscle lineages. differentiated endothelial cells exhibited neo-angiogenesis and anastomosis in vivo. this methodology for indirect lineage conversion to angioblast-like cells adds to the armamentarium of reprogramming approaches aimed at the study and treatment of ischemic pathologies.
Somatic cell reprogramming has highlighted the plasticity of adult somatic cells as well as the possibility of generating any desired cell type in unlimited amounts. Three approaches for somatic cell reprogramming based on the forced expression of transcription factors (TFs) have been described 1 . First, somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs), embryonic-like cells with the potential to generate any adult cell type 2 . Second, TFs defining or specifying target-cell identity have proven successful for the direct lineage conversion of mouse and human cells into several cell types [3] [4] [5] [6] . Finally, the fact that reprogramming, or de-differentiation to iPSCs, proceeds in a stepwise manner suggests that the process can be stopped before the acquisition of an embryonic-like signature. Indeed, coupling of a partially de-differentiated state to specific differentiation conditions has demonstrated a feasible alternative method to generate murine cardiac and neuronal cells [7] [8] [9] [10] [11] .
Here we present a method for the simple and efficient conversion of human fibroblasts to CD34 + progenitor cells with bipotent differentiation potential. We use a reprogramming strategy in which complete reprogramming to pluripotency is shortened or bypassed and the cells transition through a plastic intermediate state. This allows redifferentiation into CD34 + progenitor cells and subsequently to functional endothelial and smooth muscle cells. We thus demonstrate for the first time, to our knowledge, that a reprogramming strategy involving partial de-differentiation is feasible in human cells for the generation of multipotent progenitors.
results differentiation to angioblast-like cells
Prior to establishing our lineage-conversion conditions, we developed a robust medium suitable for the differentiation of pluripotent stem cells (PSCs) to mesodermal progenitor cells. We systematically analyzed well-known mediators of mesodermal development in different human PSC (hPSC) lines 12 . We established a mesodermal induction medium (MIM) for efficient differentiation of hPSCs to a mesodermal fate ( Fig. 1a and Supplementary Fig. 1) .
We tested MIM-mediated differentiation by assessing the expression of CD34, an early marker for mesoderm-derived progenitor cells with hematopoietic and/or endothelial and smooth muscle differentiation potential, in multiple hPSC lines ( Fig. 1b-f and Supplementary Figs. 1 and 2) . We observed a peak of CD34 + cells by day 8 in every analyzed cell line. In parallel, we observed upregulation of the vascular marker CD31 and mesodermal progenitor markers (Fig. 1b-g and Supplementary Figs. 1 and 2) accompanied by rapid downregulation of pluripotency-related markers ( Fig. 1g and Supplementary Fig. 2) . Additionally, we observed upregulation of several early markers related to hematopoiesis, including those encoded by RUNX1 and TAL1 (SCL) (Supplementary Fig. 2) . Although this initially suggested that differentiation in MIM may lead to the generation of a tripotent hemangioblast-like state (with hematopoietic, endothelial and smooth muscle differentiation potential), MIM-differentiated PSC-derived CD34 + cells ( PSC CD34 + ) did not result in the expression of hematopoietic markers at the protein level or the formation of hematopoietic colonies in standard assays.
MIM-induced CD34 + cells may thus represent a developmental stage similar to that of angioblast cells 13 , and we consequently investigated their potential to differentiate along endothelial and smooth muscle lineages. Sorting of CD34 + cells after 8 d of MIM differentiation for mesoderm commitment, followed by subsequent differentiation toward the endothelial lineage, yielded 60-90% endoglin (encoded by ENG)-and vascular endothelialcadherin (encoded by CDH5)-positive endothelial cells for all PSC lines analyzed ( Fig. 1h and Supplementary Fig. 3 ). Notably, we readily detected expression of von Willebrand factor (VWF), a mature endothelial marker and pro-coagulant protein ( Fig. 1h and Supplementary Fig. 3 ). Quantitative PCR (qPCR) analysis demonstrated upregulation of endothelial markers, but not of smooth muscle markers ( Fig. 1i and Supplementary Fig. 3) .
Similarly, we sorted PSC CD34 + cells and subjected them to smooth muscle differentiation conditions, yielding a population consisting of more than 50% smooth muscle cells as indicated by immunofluorescence staining. Using qPCR, we found significant upregulation of smooth muscle markers, including expression of high-molecular weight caldesmon type 1 (CALD1), but not of endothelial markers. With single-cell differentiation assays, we demonstrated that the MIM-differentiated PSC CD34 + cells were multipotent (Supplementary Fig. 4) .
Our data thus indicate that MIM can be used for differentiation of hPSCs to CD34 + cells with the potential to generate both endothelial and smooth muscle lineages. Moreover, CD34 + cells were generated more efficiently (at least 30%, depending on the PSC line) than in previously described protocols [14] [15] [16] . Genomewide DNA methylation and gene expression studies indicated 
conversion of human fibroblasts to angioblast-like cells
We next asked whether MIM could be coupled to partial de-differentiation or 'plastic' induction to convert human fibroblasts to CD34 + angioblast-like progenitor cells ( Fib CD34 + ). We induced plasticity by short-term exposure of fibroblasts to iPSC reprogramming conditions 7,8 followed by MIM differentiation (Fig. 2a) .
We first used retroviral approaches and the traditional four-factor combination of proteins (encoded by SOX2, OCT4 (POU5F1), KLF4 and c-MYC (MYC)) in two neonatal human fibroblast lines (HFF and BJ) and in adult human dermal fibroblasts. An 8-d exposure of cells to reprogramming factors and iPSC-like culture conditions resulted in a plastic state in the absence of pluripotent marker expression that, upon MIM differentiation for an additional 8-d period, led to the appearance of a prominent Fib CD34 + population (Fig. 2b,c and Supplementary Table 1 ). Of note, precise frequency analysis was technically difficult because our procedure involves nonclonal expanding populations of cells. We calculated angioblast conversion efficiencies by estimating the ratio between the final number of converted cells and the initial number of fibroblasts. Given that 75,000 fibroblasts gave rise to ~2 × 10 6 cells by the end of MIM commitment, of which 20%-60% were CD34 + (depending on the cell line of origin and the method used for plasticity induction), conversion efficiencies ranged between 400% and 1,200%.
We additionally asked whether the miR302 and miR367 (miR302-367) microRNA clusters, which have been demonstrated to play a role during reprogramming to iPSCs 17, 18 , could increase the efficiency of the process. We observed that inclusion of miR302-367 improved the efficiency of Fib CD34 + cell generation in some but not all lines ( Fig. 2c and Supplementary  Table 1 ). We next sought to determine the minimal requirements for the conversion of human fibroblasts to Fib CD34 + by systematic single-factor removal. We observed marginal levels of CD34 + cells, with low fluorescence intensities, when SOX2 was used alone (~5% CD34 low ), and subsequent differentiation of sorted CD34 + cells did not yield endothelial or smooth muscle cells. Other single-factor combinations did not give rise to CD34 + cells. All together, combination of the four Yamanaka factors, alongside the use of iPSC-like culture conditions, was necessary for the conversion to CD34 + cells resembling an angioblastlike state.
Similarly to PSC differentiation results, MIM differentiation led to a significant upregulation of angioblast-related markers in all conditions analyzed ( Fig. 2d) . Sorting of MIM-differentiated Fib CD34 + cells and subsequent culture in medium promoting endothelial or smooth muscle cell differentiation resulted in the upregulation of lineage-specific markers at both the RNA and protein levels ( Fig. 2e,f and Supplementary Figs. 7-9 ). Lineage conversion of human fibroblasts toward the endothelial lineage resulted in the mixed expression of markers for different endothelial subtypes, including expression of arterial, venous and lymphatic endothelial genes 19 (Supplementary Fig. 8) . Similarly, analysis of smooth muscle cell populations derived from human npg fibroblasts demonstrated mixed expression of smooth muscle markers 20 , including expression of the pericyte marker NG2 (Supplementary Fig. 9 ).
Converted endothelial cells lost many features of fibroblast gene expression and DNA methylation profiles, and they acquired characteristics of primary endothelial cells (Fig. 2g,h and Supplementary Fig. 5 ). When all samples, regardless of their method of derivation, were compared by unsupervised hierarchical clustering of the mRNA and methylation array data, two major groups were observed: pluripotent cells and differentiated cells. As expected, fibroblasts clustered more closely to differentiated cells than to PSCs ( Supplementary Fig. 5 and 6 ). Both mRNA expression and DNA methylation results were similar in terms of describing the relationships among the different cell types ( Supplementary Figs. 5 and 6) . 
conversion to angioblasts by non-integrative approaches
We observed residual expression of the Yamanaka factors transgenes upon differentiation to CD34 + cells as well as their endothelial and smooth muscle derivatives ( Supplementary Fig. 10 ). We thus pursued the establishment of non-integrative approaches for conversion of human fibroblasts to other cell types.
We chose a six-factor combination (OCT4, SOX2, KLF4, nontransforming LMYC (MYCL1), LIN28 and short hairpin RNA against p53) proven to generate human iPSCs in the presence of murine feeder layers when delivered episomally 21 (Fig. 3) . We obtained plastic reprogramming intermediates by electroporation npg of each vector followed by a 6-d resting phase before a switch to iPSC culture medium ( Fig. 3a) . After 8 d of plastic induction, expression of the pluripotency markers TRA1-60 and TRA1-81 was undetectable (Fig. 3b) . Then, the medium was changed to MIM for an additional 8 d, yielding CD34 + cells (Fig. 3c) . Sorting of Fib CD34 + cells and subsequent differentiation into endothelial and smooth muscle lineages resulted in the upregulation of cell type-specific markers at both the RNA and protein level ( Fig. 3d-g) . As observed previously, the generated endothelial and smooth muscle cells represented mixed populations of different subtypes (Fig. 3g) . Notably, we observed the rapid clearing of episomal vectors and did not detect random integration of exogenous genes in the differentiated endothelial cells (Supplementary Fig. 10 ). TRA1-60 has recently been described as the most reliable early marker for iPSC generation, with a success prediction rate of up to 90% (ref. 22 ). We did not observe detectable expression of TRA1-60 or TRA1-81 with either the non-integrative approach or the retroviral approach for plastic induction of fibroblasts ( Figs. 2b  and 3b,c and Supplementary Fig. 10 ). Furthermore, testis injection in mice of 1 million differentiated endothelial cells, including cells generated by differentiation of PSCs, did not result in teratoma formation in any of the groups analyzed after 10 weeks (Supplementary Fig. 10 ).
Functionality of converted cells in vitro and in vivo
Two well-characterized physiological hallmarks of smooth muscle cell function are calcium response and contractility 20, 23, 24 . Contraction of Fib CD34 + cell-derived smooth muscle cells occurred both spontaneously as well as upon drug stimulation ( Supplementary Fig. 11 and Supplementary Video 1). Exposure to carbachol resulted in rapid calcium transients. Of note, HEK293T human embryonic kidney cells also show calcium transients in response to carbachol, but they do not physically contract as demonstrated by their unchanged cell surface area (Supplementary Fig. 11) .
We investigated the function of Fib CD34 + cell-derived endothelial cells by measuring acetylated low-density lipoprotein (LDL) uptake, a characteristic of mature endothelial cells. The cells showed significantly higher rates of LDL uptake as compared to differentiated endothelial cells in the presence of control Alexa 488 used to measure nonspecific fluorescence background ( Fig. 3h and Supplementary Fig. 12) . The converted endothelial cells also aggregated into vessel-like structures in vitro ( Fig. 3i and Supplementary Fig. 12 ). Upon subcutaneous implantation in a Matrigel plug, the cells formed functional vessels, allowing for blood circulation, after 17 d in vivo (Fig. 4a) , demonstrating the connection of newly formed vessels to the pre-existing vasculature. Cells in the Matrigel plugs extracted from the animals at day 17 were endothelial cells as verified by Ulex europaeus lectin binding and were of human origin as determined by in situ hybridization (Fig. 4b,c) as well as by staining with antibodies specific for human CD31 and human nuclear antigen (Fig. 4d,e ).
discussion
We have established an efficient method for the conversion of neonatal and adult human fibroblasts to CD34 + angioblast-like and Ulex lectin rhodamine immunofluorescence (IF) staining (red). Note the presence of circulating red blood cells through the vessel-graft. (d) Endothelial cells derived by non-integrative-mediated conversion of human fibroblasts demonstrate anastomosis in vivo. Upon Matrigel plug extraction and processing, human specific CD31 antibody demonstrates the presence of converted endothelial cells (green). Colocalization with specific human nuclear antigen (HuNu) staining demonstrates that the generated vessels are derived from the injected converted human endothelial cells. In the rightmost images, all fluorescence channels have been merged over bright-field pictures to allow for morphological identification of circulating erythrocytes. (e) Representative high-magnification micrograph of the extracted Matrigel plugs demonstrating connection to the pre-existing vasculature upon injection of converted endothelial cells generated by non-integrative approaches. Arrows, circulating red blood cells. Scale bars: 5 µm (b,c); 50 µm (d,e). Green, CD31; magenta, HuNu; blue, nuclear staining. npg progenitor cells ( Supplementary Table 1 ). Our approach couples the generation of plastic reprogramming intermediates with subsequent induction of an angioblast fate with chemically defined MIM. These angioblast-like cells could be further differentiated into functional endothelial and smooth muscle cells.
We observed differences at both the transcriptome and methylome level when comparing our converted endothelial and smooth muscle cells to the primary cells used as positive controls. One reason could be that our generated cell populations include different subtypes of cells as compared to the primary cells (human umbilical vein endothelial cells and arterial smooth muscle cells). Alternatively, these differences could be reminiscent of experimental variation as seen between and within iPSC and embryonic stem cell lines 25 . Residual epigenetic marks from the initial fibroblasts could also account for some observed differences 6 . Furthermore, the fact that induction of 'plasticity' relies on a first phase of epigenetic erasure, which by similarity with iPSC reprogramming might imply a stochastic process, strongly suggests that the heterogeneity observed at the molecular level during the conversion process might be due to the presence of cells with varying degrees of epigenomic plasticity. Nevertheless, all the cells generated (whether differentiated from PSCs or derived by conversion of human fibroblasts) demonstrated functional properties, thus highlighting the potential of these novel conversion methodologies as well as the importance of analyzing functional parameters in reprogramming paradigms 6, 25, 26 .
Conversion to angioblast-like progenitor cells occurred in the absence of detectable iPSC colony formation, surface-marker expression and re-activation of the endogenous pluripotency transcription network, therefore considerably shortening the time required for generation of the desired cell types. Although we cannot rule out that converted cells transitioned through a pluripotent-like state, the lack of pluripotent marker expression and teratoma formation indicates that the conversion process does not result in typical iPSC features.
In contrast to a recent report describing the conversion of amniotic cells to endothelial cells 27 , this study demonstrates that shortterm induction by iPSC reprogramming conditions, followed by exposure to a chemically defined differentiation medium, is sufficient for the conversion of neonatal and adult human fibroblasts into angioblast-like progenitor cells with multipotent differentiation potential. Of note, not only the autonomous effects of the reprogramming factors but also the overall combination of stem cell culture conditions promoting cell proliferation, as exemplified by the requirement of basic fibroblast growth factor (bFGF), are crucial. Interestingly, culture conditions have also been highlighted as a critical component during the conversion process in similar studies performed in the murine system 7, 8 .
Unlike direct lineage conversion, which requires precise knowledge and screening of molecules defining target-cell identity, induction of plastic or de-differentiation states coupled to specific differentiation protocols might provide a general, more readily accessible platform toward the broader generation of clinically relevant cell types. Furthermore, whereas direct lineage conversion might be viewed as an 'unnatural' process 6 occurring in the absence of progenitor cell generation, our results and those reported for the murine system 7, 8 show the formation of intermediate progenitor states, such as seen during normal embryogenesis. This may have two major practical implications. First, the generation of progenitor cells with multilineage differentiation capacity strongly diversifies the spectra of applications as opposed to direct lineage conversion. Second, the inability to generate proliferative populations by direct lineage conversion could represent a major limitation for applications in which large numbers of cells are required 6,9 . In the case shown here, the conversion of human fibroblasts into vascular smooth muscle and endothelial cells proceeds through the generation of an expandable population of vascular progenitors with multilineage differentiation capacity. All together, our results describe a novel methodology for the reprogramming of somatic cells, and they support a complementary approach to direct lineage conversion as well as to full reprogramming to induced pluripotency for the generation of human cell types with clinical implications.
methods
Methods and any associated references are available in the online version of the paper.
Accession codes. Data sets for DNA methylation analysis and gene expression microarray analysis are available on the Gene Expression Omnibus (GSE40927).

Note: Supplementary information is available in the online version of the paper.
online methods Reagents and antibodies. The following antibodies were used at the specified concentrations: mouse anti-human CD34-APC 1:10 (130-046-703, Miltenyi), mouse anti-human CD133/2 (293C3)-PE 1:10 (130-090-853, Miltenyi), mouse anti-human CD144-PE 1:10 (VE-cadherin; 560410, BD Biosciences), mouse anti-human CD144-APC 1:10 (VE-cadherin; 348507, BioLegend), CD105-PE 1:10 (endoglin; ab60902, Abcam), mouse anti-human CD105-PE 1:10 (endoglin; 560839, BD), CD31-FITC 1:10 (555445, BD), CD117-PeCy7 1:10 (c-Kit; 339195, BD), VEGFR2-PE 1:10 (KDR; 560494, BD), mouse anti-human CD45-FITC 1:10 (130-080-202, Miltenyi), anti-human CD235a-PE 1:10 (340947, BD), mouse APC isotype control 1:10 (555751, BD), mouse FITC isotype control 1:10 (555748, BD), PeCy7 isotype control 1:10 (557872, BD), PE isotype control 1:10 (555749, BD), VE-cadherin 1:500 (555661, BD), endoglin 1:500 (M3527, DAKO), anti-von Willebrand Factor 1:200 (VWF; 7356, Millipore), calponin 1:500 (Dako, M3556), α-SMA 1:500 (AB56994, Abcam), α-SMA 1:1,000 (A5228, Sigma), PECAM-1 (M-20) 1:100 (CD31; sc1506, Santa Cruz Biotechnology) anti-human nuclei 1:100 (MAB1281, Millipore), DAPI (5 mg ml −1 ) 1:2,000 (D1306, Invitrogen), Hoechst 33342 (5 mg ml −1 ) 1:2,000 (B2261, Sigma), Alexa Fluor 488 goat anti-mouse (A11001, Invitrogen), Alexa Fluor 488 donkey anti-goat (A11055, Invitrogen), Alexa Fluor 568 donkey anti-mouse (A10037, Invitrogen) and Alexa Fluor 568 donkey anti-rabbit (A10042, Invitrogen).
Cell culture. Human ES cells, H1 (WA1, WiCell), HuES 9 (http://grants.nih.gov/stem_cells/registry/current.htm?id=40) and human iPS cells CBiPS 28 and KiPS 29 (KIPS 4F2, CBiPS 2F4) (passage 25-45) were cultured in chemically defined hES/hiPS growth medium (mTeSR 30 on growth factor-reduced Matrigel (356230, BD)-coated plates). Briefly, 70-80% confluent hES/iPS cells were treated with dispase (Invitrogen) for 7 min at 37 °C, and colonies were dispersed to small clusters and lifted carefully using a 5-ml glass pipette at a splitting ratio of ~1:4. Neonatal human fibroblasts (HFF-1, BJ; ATCC) and adult human dermal fibroblasts (HDF-693) were cultured in DMEM containing 10% FBS, 2 mM GlutaMAX (Invitrogen), 50 U ml −1 penicillin and 50 mg ml −1 streptomycin (Invitrogen). Human umbilical vein endothelial cells (HUVECs) were purchased from PromoCell and cultured in EBM medium supplemented with EGM-2 SingleQuots (cc-3162, Lonza), 2% FBS, hEGF 10 µg ml −1 and heparin 100 µg ml −1 (Sigma). Mesodermal induction medium (MIM) consists of DMEM:F12, 15 mg ml −1 stem cell-grade BSA (MP Biomedicals), 17.5 µg ml −1 human insulin (SAFC Biosciences), 275 µg ml −1 human holo-transferrin (Sigma), 20 ng ml −1 bFGF (Stemgent), 50 ng ml −1 human VEGF-165 aa (Humanzyme), 25 ng ml −1 human BMP4 (Stemgent), 450 µM monothioglycerol (Sigma) and 2.25 mM each l-glutamine and non-essential amino acids (Invitrogen). iPS/ ES-derived endothelial cells were cultivated in EBM-2 medium supplemented with EGM-2 SingleQuot kit (cc-3162, Lonza). iPS/ES-derived smooth muscle cells were cultured in SmBM medium supplemented with SmGM-2 SingleQuot kit (cc-3182, Lonza). All the cells were grown in collagen I-coated plates (BD). All cell lines were maintained in an incubator (37 °C, 5% CO 2 ) with medium changes every day (hES/iPS) or every second day (HUVEC/fibroblasts).
Directed differentiation of hES/hiPS cells in chemically defined conditions. Human ES/iPS cells cultured as described above were freshly split on Matrigel-coated plates, and we made sure the subcolonies were of small size (~300-500 cells per colony). After 24 h of recovery in mTeSR, the cells were gently washed using DMEM: F12 (Invitrogen) and allowed to grow in chemically defined MIM differentiation medium. Medium was changed every second day with addition of half the volume of medium every other day.
Single-cell differentiation assays. Upon MIM differentiation for 8 d, CD34 + angioblast-like cells were sorted and plated in collagen I-coated 48-well plates at a density of one cell per well in either EBM-2 (for endothelial differentiation) or SmBM (for smooth muscle differentiation) supplemented as described above. After 7 d in the respective differentiation conditions, cells were washed once with PBS and fixed with 4% paraformaldehyde (PFA) in 1× PBS. Following fixation, cells were blocked and permeabilized for 1 h at 37 °C with 5% BSA/5% appropriate serum/1× PBS in the presence of 0.1% Triton X-100. Subsequently, cells were incubated overnight at 4 °C with an anti-endoglin antibody in case of cells in EBM-2/EGM-2 or with an anti-calponin antibody in the case of cells in SmBM/SmGM-2. Cells were then washed thrice with 1× PBS, incubated for 1 h at 37 °C with the respective secondary antibodies and 20 min with DAPI for nuclear staining. Following incubation, cells were washed thrice with 1× PBS before microscopy analysis and scoring.
Conversion of human fibroblasts into angioblast-like CD34 + progenitor cells.
For retroviral infection, human fibroblast cells (HFF-1, BJ, HFF-693) were plated on Matrigel-coated six-well plates at 75,000 cells per well. The next day, cells were infected with an equal ratio of a combination of either four pMX-derived retroviruses encoding OCT4, SOX2, KLF4 and c-MYC (4F) or five pMX-derived retroviruses encoding OCT4, SOX2, KLF4, c-MYC and miR302-367 (4F/miRs). Scramble miRNA control (PMIRH000PA-1, SBI) was used whenever appropriate. The plates were infected by spinfection of the cells at 1,850 r.p.m. for 1 h at room temperature in the presence of polybrene (4 µg ml −1 ) and put back in the incubator without medium change. 24 h later, the medium was switched to WiCell medium composed of DMEM/F12 (Invitrogen), 20% KnockOut serum replacement, 10 ng ml −1 bFGF, 1 mM GlutaMAX, 0.1 mM non-essential amino acids and 55 µM β-mercaptoethanol; with medium changes every day. After 6 d, cells were split at a ratio of 1:3 on to Matrigelcoated six-well plates supplemented with WiCell medium for another 2 d. The cells were then washed once with DMEM/F12 and induced for differentiation for 8 d in the presence of MIM. Medium was changed every second day with addition of half the volume of medium every other day.
For episomal transfection, 2 × 10 6 cells were transfected with 1.5 µg each of pCXLE-episomal vectors encoding OCT4, SOX2, KLF4, LMYC, LIN28 and shRNA-p53 (ref. 22) (27077, 27078 and 27080, Addgene) with and without addition of pcDNA3.1 encoding for miR302-367 (6F or 6F/miRs). Fibroblasts were transfected by nucleofection (Amaxa NHDF Nucleofector Kit, VPD-1001) according to the manufacturer's instruction and plated back on to Matrigel-coated wells. Cells were then rested for 6 d in DMEM/F12 supplemented with 10% FBS, 0.1 mM non-essential amino acids and 2 mM GlutaMAX, and then the medium was switched to WiCell medium, with medium changes every day. After 6 d, cells were split at a ratio of 1:3 on to Matrigel-coated six-well plates with WiCell medium for another 2 d. The cells were then washed once with DMEM:F12 and induced for differentiation for 8 d in the presence of MIM. Medium was changed every second day with addition of half the volume of medium every other day.
RNA isolation and real-time PCR analysis. Total cellular RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer's recommendations. 2 µg of DNase 1-(Invitrogen) treated total RNA was used for cDNA synthesis using the SuperScript II Reverse Transcriptase kit for RT-PCR (Invitrogen). Real-time PCR was performed using the SYBR Green PCR Master Mix (Applied Biosystems). The levels of expression of respective genes were normalized to corresponding GAPDH values and are shown as fold change relative to the value of the control sample. All the samples were done in triplicate. A list including precise mRNA fold-change quantifications of the qPCR data summarized in Figures 1-3 is provided in Supplementary Table 2 . The primers used for real-time PCR experiments are listed in Supplementary Table 3 .
Flow cytometry analysis. Human ES/iPS cells undergoing directed differentiation, lineage-converted CD34 + cells or their respectively derived endothelial cells were harvested using TrypLE (Invitrogen), washed once with PBS and further incubated with the corresponding antibodies in the presence of FACS blocking buffer (1× PBS/10% FCS) for 1 h on ice in the absence of light. After incubation, cells were washed thrice with 1 ml of FACS blocking buffer and resuspended in a total volume of 200 µl before analysis. A minimum of 10,000 cells in the living population were analyzed by using a BD LSRII flow cytometry machine equipped with five different lasers and the BD FACSDiva software. Percentages are presented after the subtraction of isotype background and refer to the total living population analyzed. Results are representative of at least three independent experiments with a minimum of two technical replicates per experiment.
Cell sorting. After 8 d of differentiation, CD34 + cells were stained as described above and sorted by using a BDAria II FACS sorter (BD Biosystems). Alternatively, CD34 + cells were enriched using anti-CD34-conjugated magnetic beads (Miltenyi) according to the manufacturer's instructions with slight modifications. Briefly, up to 10 9 cells were incubated with constant mixing at 4 °C with 100 µl of the corresponding magnetic beads in the presence of 100 µl of Fc-blocking solution in a total volume of 500 µl FACS blocking buffer. After 1 h, cells were sorted by two consecutive rounds of column separation to increase purity by applying MACS separation magnets. Shortly, cells were passed through the first MS separation column, which allowed the binding of labeled cells. Nonlabeled cells were washed thoroughly with 3 ml FACS blocking buffer before elution of the labeled fraction. Eluted labeled cells were then subjected to a second purification step as described above.
Differentiation of CD34 + cells to endothelial cells. PSC and lineage-converted CD34 + cells, isolated by MACS or by FACS sorting after 8 d of differentiation in MIM, were plated in collagen I-coated plates (50,000 cells per well in a 12-well plate) and cultured in EBM-2/EGM-2 (Lonza) with medium changes every day. After 5-8 d in culture, upon reaching 90% confluence, cells were split 1:4 with TrypLE (Invitrogen). The cells were cultured for at least eight passages.
Differentiation of CD34 + cells to smooth muscle cells. PSC and lineage-converted CD34 + cells, isolated by MACS or by FACS sorting after 8 d of differentiation in MIM, were plated in collagen I-coated plates (50,000 cells per well in a 12-well plate) and cultured in SmBM/SmGM-2 (Lonza) with medium changes every day. After 5-8 d in culture, upon reaching 90% confluence, cells were split 1:4 with TrypLE (Invitrogen). The cells were cultured for at least eight passages.
DNA methylation analysis. Illumina 450K Infinium Methylation
Arrays were normalized and preprocessed in Genome Studio. Probes with missing values were removed. A filter for an average β-value difference between groups (PSCs, fibroblasts, primary human arterial smooth muscle cells (PriSMCs), primary human umbilical vein endothelial cells (PriECs), PSC→CD34 + progenitor cells, PSC→endothelial cells (iECs), converted endothelial cells (cECs), PSC→smooth muscle cells (iSMCs), converted smooth muscle cells (cSMCs)) of ≥0.3 was applied. The resulting probes were used for ANOVA analysis using R scripts with a P-value filter of <0.0001 (at this point, 30,000 probes remained). Probes with a β-value difference of ≥0.3 ((max -min) > = 0.3) were used. ANOVA (P < 0.05; variance = 0.58) was applied to obtain statistically significant differentially methylated probes among the five groups in both SMC and EC sample groups. The resulting probes (Supplementary Data) were used for hierarchical clustering using Cluster 3.0 with complete linkage. Venn Diagram Plotter (http://omics.pnl. gov/software/VennDiagramPlotter.php) was used to generate area-proportional Venn diagrams.
Gene expression microarray analysis. The following groups were analyzed: PSCs, fibroblasts, PriSMCs, PriECs, iECs, cECs, iSMCs and cSMCs. Briefly, total RNA was extracted from collected sample pellets (Ambion mirVana; Applied Biosystems) according to the manufacturer's protocol. RNA quantity (Qubit RNA BR Assay Kits; Invitrogen) and quality (RNA6000 Nano Kit; Agilent) were determined to be optimal for each sample before further processing. 200 ng RNA per sample was amplified using the Illumina Total Prep RNA Amplification Kit according to the manufacturer's protocol and quantified as above. 750 ng RNA per sample was hybridized to Illumina HT-12v3 Expression BeadChips, scanned with an Illumina iScan Bead Array Scanner and checked for quality control in GenomeStudio and the lumi bioconductor package. All RNA processing and microarray hybridizations were performed in house according to the manufacturer protocols. Differential expression was defined as a minimum 2× fold change and multiple testing-corrected P < 0.05 by ANOVA. The resulting probes (Supplementary Data) were used for hierarchical clustering using Cluster 3.0 with complete linkage. Probes with minimum gene expression differences between groups of 2× fold change were obtained (Supplementary Data). Venn Diagram Plotter was used to generate area-proportional Venn diagrams.
npg Determination of copy number by quantitative PCR. Briefly, total DNA was extracted using the Qiagen DNeasy Blood & Tissue kit (QIAGEN). The purity and quantity of DNA were measured using a NanoDrop 8000 spectrophotometer (Thermo Scientific) and then used as templates for absolute quantitation by qPCR assay 22 . The primers used are listed in Supplementary Table 3 , and their amplification efficiencies as well as specificity were checked by performing standard curve and melting curve analyses.
Immunocytochemistry and fluorescence microscopy. Briefly, cells were washed thrice with PBS and fixed using 4% PFA in 1× PBS. After fixation, cells were blocked and permeabilized for 1 h at 37 °C with 5% BSA/5% appropriate serum/1× PBS in the presence of 0.1% Triton X-100. Subsequently, cells were incubated with the indicated primary antibody either for 1 h at room temperature or overnight at 4 °C. The cells were then washed thrice with 1× PBS and incubated for 1 h at 37 °C with the respective secondary antibodies and 20 min with DAPI or Hoechst 33342. Cells were washed thrice with 1× PBS before analysis. Sections were analyzed by using an Olympus 1X51 upright microscope equipped with epifluorescence and TRITC, FITC and DAPI filters. Confocal image acquisition was performed using a Zeiss LSM 780 laser scanning microscope (Carl Zeiss Jena) with 20×, 40× or 63× immersion objectives.
Acetylated LDL uptake assay and vascular tube-like structure formation assay. In short, 80% confluent endothelial cells derived from human ES/iPS cells were incubated with 10 µg ml −1 Dil-Ac-LDL (L23380, Molecular Probes) for 3 h in DMEM:F12. The cells were washed three times with PBS, dissociated using TrypLE and analyzed by flow cytometry.
Briefly, to assess the formation of capillary structures, a suspension of 4 ×10 5 endothelial cells per ml in the presence EBM-2/ EGM-2 was prepared. Subsequently, 100 µl per well was dispensed on flat-bottom 96-well plates coated with Matrigel (BD). Tube formation was observed after 24 h of incubation, and a minimum of three replicates per experiment was analyzed.
Hematopoietic colony-forming assays. Hematopoietic clonogenic assays were performed in 35-mm low-adherent plastic dishes (Stem Cell Technologies) using 1.1 ml per dish of methylcellulose semisolid medium (MethoCult H4434 classic, Stem Cell Technologies) according to the manufacturer's instructions. Briefly, enriched CD34 + cells were sorted and immediately plated at various densities: 1.5 × 10 3 , 3 × 10 3 and 6 × 10 3 cells per ml. All assays were performed in duplicate. After 21 d of incubation, plates were analyzed for the presence of both colony-forming units (CFU) and burst-forming units (BFU).
Animals. Mice were housed in an AAALAC-accredited facility and in compliance with European Directive related to Laboratory animal protection. All murine experiments were conducted with approval of the local laboratory animal Ethics Committee of Toulouse Sanofi Research Center. NOD. Cg-PrkdcscidIl2rgtm1Wjl /SzJ mice (or NOD-Scid IL2rγnull abbreviated as NSG; age, 7 weeks; weight, 20 g) were purchased from Charles River Laboratories, housed in air-flow racks on a restricted-access area and maintained on a 12-h light/dark cycle at a constant temperature (22 ± 1 °C). Teratoma experiments were conducted with approval of the Salk Institute Institutional Animal Care and Use Committee (IACUC).
Matrigel plug assay. Anesthesia was induced using a mixture of xylazine (Rompun 2%, Bayer) at 10 mg per kilogram body weight and ketamine (Imalgene1000, Merial) at 100 mg per kilogram body weight in NaCl at 0.9%, i.p. injected at a dose of 10 ml per kilogram body weight. The animals' backs were shaved and swabbed with hexomedine. Prior to injection, HUVECs, HUES9-, KiPS-, BJ 6F-and BJ 6F/miRs-derived endothelial cells were harvested using TrypLE (Invitrogen). A total of 1 × 10 6 cells were resuspended in 500 µl of cold Matrigel (Matrigel basementmembrane matrix from BD adjusted to 9.8 mg ml −1 with PBS) supplemented with 150 ng of bFGF. We then injected Matrigel solutions containing or lacking cells subcutaneously in the backs of mice, carefully positioning the needle between the epidermis and the muscle layer. Seventeen days later, mice were sacrificed, and the Matrigel plugs were removed by a wide excision of the back skin, including the connective tissues (skin and all muscle layers).
Tissue processing and analyses. For immunohistochemistry (IHC), in situ hybridization (ISH) or immunofluorescence (IF) analysis, cell-containing implants with associated connective tissues were fixed with Accustain (SIGMA) for 24 h, dehydrated through an ethanol series and then processed for paraffin embedding before being sliced with a microtome. Slices from paraffinembedded samples were stained with appropriate antibodies or probes. Alternatively, plugs were harvested and fixed with a 4% paraformaldehyde solution overnight at 4 °C, washed thrice in PBS and then incubated in a glucose solution (30%) for another 48 h before being sliced (45 µm thickness) with a cryostat (Leica). Both methodologies were equally successful in identifying neovasculature derived from human cells.
For IHC, slides were stained with an anti-human CD31 monoclonal antibody and then incubated with biotin-labeled secondary antibody followed by incubation with streptavidin-HRP (Ventana Roche).
For ISH, slides were hybridized according to the manufacturer's protocol with an Alu probe (780-2845, Ventana Roche) and then labeled with the ISH iView Blue Detection Kit (760-092, Ventana Roche).
For IHC and ISH, images were then captured with a camera mounted on a light microscope (Nikon E-800).
For immunofluorescence assays, slides were stained with either rhodamine-labeled Ulex europaeus agglutinin I (UEA I, a marker for human endothelial cells, Vector Laboratories) or PECAM-1 (M-20) (CD31; sc1506, Santa Cruz Biotechnology) and anti-human nuclei 1:100 (MAB1281, Millipore) counterstained with DAPI. Images were captured with confocal microscopes (Zeiss, LSM 510 or LSM780).
Calcium live-cell imaging. Subconfluent cells were washed with DMEM:F12 and incubated for 45 min with 1 µM Fluo-4/AM (Molecular Probes) in 0.5% BSA, DMEM:F12 in an incubator at 37 °C, 95% CO 2 . After a washing step to remove unloaded dye, cells responses to 100 µM carbachol or vehicle (water) were imaged in HEPES-buffered, phenol red-free DMEM:F12 in a wide-field fluorescence microscope (Olympus BX61WI) equipped for fast fluorescence imaging. Image capture was performed with Metamorph and an EM-CCD camera (Hamamatsu). Image analysis was carried npg
